Developer docs
API playgroundTry for free, no card

Search company profiles

Heraeus Medical

Full company profile

uuid000gnxe

Namestring
Heraeus Medical
Legal namestring
Heraeus Medical GmbH
Company typeenum
Private
Founded yearint
1851
Descriptiontext

Heraeus Medical GmbH is a privately held medical device company and division of the family-owned Heraeus Group (Heraeus Holding GmbH), headquartered in Wehrheim, Germany. The company manufactures bone cements, mixing and application systems, pulse lavage systems, and bioresorbable bone substitute materials for orthopaedic and trauma surgery, with end users being orthopaedic surgeons, operating theatre staff, pharmacists, and the hospitals and ambulatory surgical centres in which they practice. Its portfolio is anchored by the PALACOS and COPAL bone cement brands (including antibiotic-loaded variants for infection prevention and management), OSTEOPAL cements for spinal surgery, and complementary handling systems such as PALAMIX, PALABOWL, palaJet, and PALAVAGE. Since 2025 the company has expanded into regenerative orthopaedics via the acquisition of INNOTERE GmbH (Radebeul) and the launch of the heracure brand: heracure one, a ready-to-use calcium phosphate paste in prefilled syringes, and heracure 3D, 3D-printed scaffolds manufactured through a patented process, both built on the proprietary BONEPACE Technology alpha-tricalcium phosphate platform that converts to bone-mineral-like hydroxyapatite in situ.

The company generates revenue primarily through direct B2B sales of medical devices and consumables, with distribution supplemented by a network of 70+ distribution partners reaching over 90 countries across Europe, Asia Pacific, North America, the Middle East, Latin America, and Africa. Pricing is quote-based and not publicly disclosed; the go-to-market combines an enterprise field sales motion targeted at orthopaedic departments and hospital systems with event-driven engagement at major orthopaedic congresses (EBJIS, BOA, DKOU, SOFCOT). Customer education and clinical engagement are delivered through PALACADEMY, an in-house learning platform that has trained over 22,000 healthcare professionals across 53 countries since 2006 via 900+ live and digital events, functioning as a quasi-developer-relations channel for surgeon adoption.

Operationally, the company holds ISO 13485 (DIN EN and MDSAP), ISO 14001, and ISO 45001 certifications, has secured EU MDR certification for the heracure line, COPAL G+V, PALACOS (without gentamicin), and PALAMIX during 2025-2026, and has achieved EcoVadis Gold status (top 5%) for two consecutive years. Heraeus Medical does not publicly disclose standalone revenue and is currently navigating the recovery from a 2025 packaging-related production halt at its main site, with first product releases from resumed pouch bone cement production expected from mid-July 2026. The US market is explicitly excluded from the current commercial footprint.

Short descriptiontext

Heraeus Medical GmbH is a Wehrheim, Germany-based medical device company (division of Heraeus Group) that manufactures bone cements, mixing and lavage systems, and bioresorbable bone substitute materials for orthopaedic and trauma surgeons across more than 90 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersYardley, United States
HQ citystring
Yardley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orthopedic bone cements, surgical biomaterials, joint arthroplasty devices, bone regeneration materials, medical mixing systems
Industry2 codes
1Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
CodeHLAHAEAGPrimaryYes
2Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle)
CodeHLAHAEAAPrimaryNo
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Orthopedic Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device and Biomaterial Sales
TypeHardware Sales
Description

Heraeus Medical generates revenue through the sale of medical devices including bone cements, biomaterials, mixing systems, and accessories for orthopaedic and trauma surgery. Products are sold directly or through distribution partners in over 90 countries.

heraeus-medical.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1PALACOS
Description

Bone cements for implant fixation and infection prevention

heraeus-medical.com
+9 more records
Core offering1 text field

Heraeus Medical manufactures orthopedic bone cements under the PALACOS, COPAL, and OSTEOPAL brands for implant fixation in joint replacement and spinal surgery, antibiotic-loaded cements for infection prevention, and complementary mixing and pulse lavage systems (PALAMIX, PALABOWL, palaJet, PALAVAGE). The company also sells bioresorbable bone substitute materials (heracure one paste and heracure 3D printed scaffolds) for regenerative orthopedics, supported by the PALACADEMY education platform for healthcare professionals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 22,000 healthcare professionals trained through PALACADEMY education programs
+2 more records
Product overview1 text field

Heraeus Medical is a leader in bone cements and biomaterials for surgical orthopaedics and trauma surgery. The product portfolio centers on bone cements (PALACOS, COPAL, OSTEOPAL brands) for implant fixation in joint replacement surgery, with complementary mixing and lavage accessories (PALAMIX, PALABOWL, palaJet, PALAVAGE). The recently launched heracure line (heracure one, heracure 3D) expands into resorbable biomaterials for regenerative orthopedics following the 2025 acquisition of INNOTERE GmbH. The PALACADEMY educational platform provides training and resources for healthcare professionals. All products focus on improving surgical outcomes in bone and joint surgery, infection management, and bone regeneration.

Product and service12 records
1PALACOS bone cements
CategoryBone Cements
2COPAL bone cements
CategoryBone Cements
3OSTEOPAL bone cements
CategoryBone Cements
4heracure one
CategoryBone Regeneration Biomaterials
5heracure 3D
CategoryBone Regeneration Biomaterials
6PALAMIX
CategoryCement Mixing and Application Systems
7PALABOWL
CategoryCement Mixing and Application Systems
8palaJet
CategoryPulse Lavage Systems
9palaJet AC
CategoryPulse Lavage Systems
10PALAVAGE
CategoryPulse Lavage Systems
11pro All-In-One Fixation System
CategoryCement Mixing and Application Systems
12PALACADEMY
CategoryEducation and Training Services
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

INNOTERE GmbH, based in Radebeul, Germany, was acquired by Heraeus Medical in 2025. The company develops and manufactures innovative calcium phosphate-based biomaterials for bone regeneration. The integration began at the start of 2025 and was completed in the last months of 2025. INNOTERE will continue to operate from its Radebeul location and brings highly skilled experts with extensive know-how in resorbable biomaterials.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global orthopedic medical device leader with deep presence in joint reconstruction implants (hip, knee, shoulder) where Heraeus Medical's PALACOS bone cements are commonly used. Direct adjacency through cement usage in their primary implant portfolio makes them the closest comparable broad incumbent.

TypeBroad incumbent
Description

Orthopedic and recovery sciences company (now part of Enovis) with joint reconstruction and surgical implant offerings. Comparable as an orthopedic incumbent addressing similar hospital and surgical center customers with adjacent product categories.

TypeBroad incumbent
Description

Johnson & Johnson's orthopedic arm covering joint reconstruction, trauma, and spine. Comparable as a broad incumbent that addresses the same end-customers (orthopedic surgeons) and overlapping procedure types where bone cements and bone substitutes are utilized.

TypeDirect peer
Description

German medical device company that directly competes in bone cements and orthopedic surgical supplies with the Aesculap division. Most direct head-to-head competitor with Heraeus Medical in PMMA bone cements for joint arthroplasty in European markets.

TypeBroad incumbent
Description

Diversified medical technology leader with significant spinal surgery and bone biologics franchises. Comparable as a broad incumbent competing in spinal bone cement (OSTEOPAL) and orthobiologics (heracure) market segments.

TypeBroad incumbent
Description

Major diversified orthopedic medical device company with significant joint reconstruction and trauma businesses that consume bone cements and biologics. Comparable as a full-spectrum orthopedic incumbent competing for the same hospital procurement budgets.

TypeBroad incumbent
Description

UK-headquartered orthopedic and wound care company with established hip and knee reconstruction portfolios. Direct overlap with Heraeus Medical in joint replacement supply chain and hospital channel relationships across Europe and globally.

TypeDirect peer
Description

Orthopedic device company focused on joint replacement implants and bone cement products. Directly comparable as a mid-sized orthopedic player with bone cement offerings competing for the same hospital arthroplasty accounts.

TypeDirect peer
Description

France-based specialty manufacturer focused on bone cements, bone substitutes, and surgical adhesives for orthopedic applications. Closely comparable as a focused bone cement and biomaterial specialist with overlapping surgeon customer base.

TypeDirect peer
Description

Orthopedic and spine medical device company with bone graft substitute and biologic offerings. Comparable as a peer operating in adjacent bone regeneration and spinal surgery categories where Heraeus Medical's OSTEOPAL and heracure compete.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Heraeus Medical

Orthopedic Medical Devicesheraeus-medical.com

Heraeus Medical GmbH is a Wehrheim, Germany-based medical device company (division of Heraeus Group) that manufactures bone cements, mixing and lavage systems, and bioresorbable bone substitute materials for orthopaedic and trauma surgeons across more than 90 countries.

What Heraeus Medical does

Heraeus Medical GmbH is a privately held medical device company and division of the family-owned Heraeus Group (Heraeus Holding GmbH), headquartered in Wehrheim, Germany. The company manufactures bone cements, mixing and application systems, pulse lavage systems, and bioresorbable bone substitute materials for orthopaedic and trauma surgery, with end users being orthopaedic surgeons, operating theatre staff, pharmacists, and the hospitals and ambulatory surgical centres in which they practice. Its portfolio is anchored by the PALACOS and COPAL bone cement brands (including antibiotic-loaded variants for infection prevention and management), OSTEOPAL cements for spinal surgery, and complementary handling systems such as PALAMIX, PALABOWL, palaJet, and PALAVAGE. Since 2025 the company has expanded into regenerative orthopaedics via the acquisition of INNOTERE GmbH (Radebeul) and the launch of the heracure brand: heracure one, a ready-to-use calcium phosphate paste in prefilled syringes, and heracure 3D, 3D-printed scaffolds manufactured through a patented process, both built on the proprietary BONEPACE Technology alpha-tricalcium phosphate platform that converts to bone-mineral-like hydroxyapatite in situ.

The company generates revenue primarily through direct B2B sales of medical devices and consumables, with distribution supplemented by a network of 70+ distribution partners reaching over 90 countries across Europe, Asia Pacific, North America, the Middle East, Latin America, and Africa. Pricing is quote-based and not publicly disclosed; the go-to-market combines an enterprise field sales motion targeted at orthopaedic departments and hospital systems with event-driven engagement at major orthopaedic congresses (EBJIS, BOA, DKOU, SOFCOT). Customer education and clinical engagement are delivered through PALACADEMY, an in-house learning platform that has trained over 22,000 healthcare professionals across 53 countries since 2006 via 900+ live and digital events, functioning as a quasi-developer-relations channel for surgeon adoption.

Operationally, the company holds ISO 13485 (DIN EN and MDSAP), ISO 14001, and ISO 45001 certifications, has secured EU MDR certification for the heracure line, COPAL G+V, PALACOS (without gentamicin), and PALAMIX during 2025-2026, and has achieved EcoVadis Gold status (top 5%) for two consecutive years. Heraeus Medical does not publicly disclose standalone revenue and is currently navigating the recovery from a 2025 packaging-related production halt at its main site, with first product releases from resumed pouch bone cement production expected from mid-July 2026. The US market is explicitly excluded from the current commercial footprint.

Heraeus Medical firmographics

Firmographics
Name
Heraeus Medical
Legal name
Heraeus Medical GmbH
Website
https://heraeus-medical.com
Company type
Private
Founded year
1851
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Heraeus Medical GmbH is a Wehrheim, Germany-based medical device company (division of Heraeus Group) that manufactures bone cements, mixing and lavage systems, and bioresorbable bone substitute materials for orthopaedic and trauma surgeons across more than 90 countries.
Ownership category
akta.pro rank

Heraeus Medical industry classification

Industry
Product category
Orthopedic Medical Devices
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
akta.pro secondary industry
Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle) (HLAHAEAA)

Keywords

  • Orthopedic bone cements
  • Surgical biomaterials
  • Joint arthroplasty devices
  • Bone regeneration materials
  • Medical mixing systems

Where Heraeus Medical is headquartered

Location

Headquarters

HQ city
Yardley
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Heraeus Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Medical Device and Biomaterial Sales: Heraeus Medical generates revenue through the sale of medical devices including bone cements, biomaterials, mixing systems, and accessories for orthopaedic and trauma surgery. Products are sold directly or through distribution partners in over 90 countries.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Heraeus Medical product offering

Product offering

Core offering

Heraeus Medical manufactures orthopedic bone cements under the PALACOS, COPAL, and OSTEOPAL brands for implant fixation in joint replacement and spinal surgery, antibiotic-loaded cements for infection prevention, and complementary mixing and pulse lavage systems (PALAMIX, PALABOWL, palaJet, PALAVAGE). The company also sells bioresorbable bone substitute materials (heracure one paste and heracure 3D printed scaffolds) for regenerative orthopedics, supported by the PALACADEMY education platform for healthcare professionals.

Product overview

Heraeus Medical is a leader in bone cements and biomaterials for surgical orthopaedics and trauma surgery. The product portfolio centers on bone cements (PALACOS, COPAL, OSTEOPAL brands) for implant fixation in joint replacement surgery, with complementary mixing and lavage accessories (PALAMIX, PALABOWL, palaJet, PALAVAGE). The recently launched heracure line (heracure one, heracure 3D) expands into resorbable biomaterials for regenerative orthopedics following the 2025 acquisition of INNOTERE GmbH. The PALACADEMY educational platform provides training and resources for healthcare professionals. All products focus on improving surgical outcomes in bone and joint surgery, infection management, and bone regeneration.

Differentiator

Problem solved

Functional benefit

Brands

  • PALACOS: Bone cements for implant fixation and infection prevention
  • COPAL
  • OSTEOPAL
  • heracure
  • PALAMIX
  • PALABOWL
  • palaJet
  • PALAVAGE
  • PALACADEMY
  • pro All-In-One Fixation System

Products and services

  • PALACOS bone cements
  • COPAL bone cements
  • OSTEOPAL bone cements
  • heracure one
  • heracure 3D
  • PALAMIX
  • PALABOWL
  • palaJet
  • palaJet AC
  • PALAVAGE
  • pro All-In-One Fixation System
  • PALACADEMY

Quantifiable outcome

  • Over 22,000 healthcare professionals trained through PALACADEMY education programs
  • +2 more outcomes

Companies that use Heraeus Medical

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Heraeus Medical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Heraeus Medical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • INNOTERE GmbHcoreStrategic or Co-development Partner · 1 January 2025INNOTERE GmbH, based in Radebeul, Germany, was acquired by Heraeus Medical in 2025. The company develops and manufactures innovative calcium phosphate-based biomaterials for bone regeneration. The integration began at the start of 2025 and was completed in the last months of 2025. INNOTERE will continue to operate from its Radebeul location and brings highly skilled experts with extensive know-how in resorbable biomaterials.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Heraeus Medical competitors and assessment

Company assessment

Broad incumbents

  • Zimmer Biomet: Global orthopedic medical device leader with deep presence in joint reconstruction implants (hip, knee, shoulder) where Heraeus Medical's PALACOS bone cements are commonly used. Direct adjacency through cement usage in their primary implant portfolio makes them the closest comparable broad incumbent.
  • DJO (Enovis): Orthopedic and recovery sciences company (now part of Enovis) with joint reconstruction and surgical implant offerings. Comparable as an orthopedic incumbent addressing similar hospital and surgical center customers with adjacent product categories.
  • DePuy Synthes (Johnson & Johnson MedTech): Johnson & Johnson's orthopedic arm covering joint reconstruction, trauma, and spine. Comparable as a broad incumbent that addresses the same end-customers (orthopedic surgeons) and overlapping procedure types where bone cements and bone substitutes are utilized.
  • Medtronic (Spine & Biologics): Diversified medical technology leader with significant spinal surgery and bone biologics franchises. Comparable as a broad incumbent competing in spinal bone cement (OSTEOPAL) and orthobiologics (heracure) market segments.
  • Stryker: Major diversified orthopedic medical device company with significant joint reconstruction and trauma businesses that consume bone cements and biologics. Comparable as a full-spectrum orthopedic incumbent competing for the same hospital procurement budgets.
  • Smith+Nephew: UK-headquartered orthopedic and wound care company with established hip and knee reconstruction portfolios. Direct overlap with Heraeus Medical in joint replacement supply chain and hospital channel relationships across Europe and globally.

Direct peers

  • B. Braun Melsungen: German medical device company that directly competes in bone cements and orthopedic surgical supplies with the Aesculap division. Most direct head-to-head competitor with Heraeus Medical in PMMA bone cements for joint arthroplasty in European markets.
  • Exactech: Orthopedic device company focused on joint replacement implants and bone cement products. Directly comparable as a mid-sized orthopedic player with bone cement offerings competing for the same hospital arthroplasty accounts.
  • Teknimed: France-based specialty manufacturer focused on bone cements, bone substitutes, and surgical adhesives for orthopedic applications. Closely comparable as a focused bone cement and biomaterial specialist with overlapping surgeon customer base.
  • Orthofix Medical: Orthopedic and spine medical device company with bone graft substitute and biologic offerings. Comparable as a peer operating in adjacent bone regeneration and spinal surgery categories where Heraeus Medical's OSTEOPAL and heracure compete.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Heraeus Medical social profiles

Digital presence

Heraeus Medical compliance and trust

Trust signal

Compliance9 records

Heraeus Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Heraeus Medical leadership team

Management profile

Number of profiles

Profiles2 records

Heraeus Medical subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Heraeus Medical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Heraeus Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Heraeus Medical

What does Heraeus Medical do?

Heraeus Medical manufactures orthopedic bone cements under the PALACOS, COPAL, and OSTEOPAL brands for implant fixation in joint replacement and spinal surgery, antibiotic-loaded cements for infection prevention, and complementary mixing and pulse lavage systems (PALAMIX, PALABOWL, palaJet, PALAVAGE). The company also sells bioresorbable bone substitute materials (heracure one paste and heracure 3D printed scaffolds) for regenerative orthopedics, supported by the PALACADEMY education platform for healthcare professionals.

Is Heraeus Medical a public or private company?

Heraeus Medical is a private company. It is classified as corporate owned and is currently operating.

When was Heraeus Medical founded?

Heraeus Medical was founded in 1851. It employs 501 to 1,000 people.

Where is Heraeus Medical based?

Heraeus Medical is headquartered in Yardley, United States, in the North America region.

How does Heraeus Medical make money?

One revenue line is on record: medical Device and Biomaterial Sales.

Who are Heraeus Medical's main competitors?

Broad incumbents on record are Zimmer Biomet, DJO (Enovis), DePuy Synthes (Johnson & Johnson MedTech), Medtronic (Spine & Biologics), Stryker and Smith+Nephew. Direct peers are B. Braun Melsungen, Exactech, Teknimed and Orthofix Medical.

Does Heraeus Medical have an API?

No public API is recorded for Heraeus Medical.

What industry is Heraeus Medical in?

Heraeus Medical's product category is Orthopedic Medical Devices. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAHAEAA, Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle). Its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comKey Players and Competitive Overview of the Embolotherapy MarketThe embolotherapy market is projected to reach $7.33 billion by 2030, growing at a compound annual growth rate of 8.6%, driven by increasing oncology patients, demand for organ-preserving therapies, and advancements in liquid embolic agents and imaging technologies. In November 2024, Merit Medical Systems Inc. acquired the Lead Management Portfolio from Cook Medical for approximately $210 million to expand its electrophysiology and cardiac rhythm management segments. In April 2024, Heraeus Medical GmbH launched COPAL G+C, its first bone cement product certified under the Medical Device Regulation, designed to target pathogens linked to prosthetic joint infections.openPR.comBiomaterials Market to Reach USD 78.8 Billion by 2035 as Advanced Implants, Regenerative Medicine, and Sustainable Materials Drive Global GrowthMarketGenics Global Research published a report projecting the global biomaterials market to grow from USD 40.8 billion in 2025 to USD 78.8 billion by 2035, representing a compound annual growth rate of 6.8% over the forecast period. The metallic biomaterials segment currently holds approximately 42% market share, driven by orthopedic, dental, and cardiovascular applications, while North America leads regionally and Asia Pacific emerges as the fastest-growing market. Heraeus Medical expanded its regenerative orthopedics portfolio in October 2025 through integration of INNOTERE GmbH, and Covation Biomaterials launched a bio-based alternative called bioPTMEG in April 2025.The GuardianNHS hip and knee operations threatened by bone cement supply shortageA global supply issue from Heraeus Medical, the NHS's main bone cement supplier based in Germany, has caused a shortage that could delay hip and knee replacements and other planned surgeries. The NHS has supply for approximately two weeks with an estimated gap of six to eight weeks following a packaging fault that has temporarily halted production at the supplier's main site. Hospitals have been ordered to direct supplies to trauma and urgent care, with campaigners describing the news as a "crushing blow" to patients already waiting in pain.PR NewswireReduce Revisions Initiative Launched to Promote Best Practices for Total Joint Replacement SurgeryThe Reduce Revisions Initiative was launched on November 12, 2018, as a program to support orthopedic professionals in improving outcomes of total joint arthroplasty (TJA), with a focus on reducing the need for revision surgeries. In the US, over 1 million total knee and hip replacement procedures are performed annually, with over 100,000 requiring revision, numbers expected to grow significantly by 2030. The initiative is sponsored by Heraeus Medical and will create educational content and collaboration forums for surgeons, nurses, and healthcare administrators across areas including infection prevention, fixation optimization, and patient involvement.Med Device OnlineHeraeus Medical Components Expands Neuromodulation Capabilities With Acquisition Of Evergreen Medical TechnologiesHeraeus Medical Components has acquired Evergreen Medical Technologies and its subsidiary PhysioTest to expand its neuromodulation capabilities. The acquisition integrates Evergreen's engineering expertise with Heraeus's global manufacturing infrastructure to help medical device customers accelerate innovation in therapy areas for nervous system diseases.PR NewswireHeraeus Medical to Introduce Medium Viscosity Bone Cement and Vacuum Mixing System Innovations at AAOS 2018 Annual MeetingHeraeus Medical announced new additions to its PALACOS® bone cement portfolio, including medium viscosity bone cement and two mixing systems (PALAMIX® and PALABOWL®), to be showcased at the American Academy of Orthopedic Surgeons Annual Meeting in New Orleans from March 6–10, 2018. The company simultaneously shifted its US distribution model, moving from exclusive distributor sales to direct-to-customer sales for PALACOS® products. Heraeus Medical, which already operates a direct sales model in Europe, Australia, and other regions, is extending this approach to US customers to provide earlier access to its technologies.PR NewswireCINDE announces: New Heraeus Costa Rica facility expected to produce over two million guidewires in 2018 for medical device companiesHeraeus Medical Components opened a new 5,400 m² manufacturing facility in Cartago, Costa Rica, replacing its earlier San Jose location that began operations in 2012. The facility, which employs over 160 workers with plans to double headcount by 2020, is expected to produce over two million cardiovascular access guidewires in 2018 for local and U.S.-based medical device companies. Costa Rica President Luis Guillermo Solís attended the grand opening ceremony, describing the expansion as evidence of Costa Rica's qualifications as an investment destination.PR NewswireHeraeus Medical Announces PALACOS® Bone Cement is Now Available Direct in the United StatesHeraeus Medical began selling PALACOS bone cement directly in the US on January 3, 2018, through its affiliate Heraeus Medical LLC. The product, used in over 30 million cases, is now available to US customers via the company's integrated ordering process.